AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03838952
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each pack: Jia Wei Xiao Yao San granule(5 gm), Gou Teng granule (1.1 gm),and Ba Ji Tian (1.1 gm), 2 times per day for 12 weeks.
Trial: NCT03101878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline .9%
Trial: NCT02999178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04511273
Drug: Follow up of female sexual function
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50mg once daily for treatment of overactive bladder symptoms
Trial: NCT01524653
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg po od
Trial: NCT01524653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg po od
Trial: NCT01458405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, blinded, intracoronary infusion of a placebo solution
Trial: NCT00421005
Drug: fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations
Trial: NCT03703908
Drug: CCX140-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered tablet
Trial: NCT04428203
Drug: Epidiolex Oral Liquid Product
RxNorm normalized name: Epidiolex Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg Oral solution
Trial: NCT04428203
Drug: Epidiolex Oral Liquid Product
RxNorm normalized name: Epidiolex Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg oral solution
Trial: NCT00379756
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT00260481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient placebo medications for 39 days.
Trial: NCT02857842
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00386009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken by mouth once a day for 12 weeks.
Trial: NCT00585780
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets identical in appearance and dosing schedule as the active study medication was utilized
Trial: NCT03977649
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo sc every 4 weeks
Trial: NCT00769964
Drug: VA111913 TS / placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04366050
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02746796
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02746796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01946386
Drug: LEO 90100 Aerosol, foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The products will be applied on 6 test sites (according to random assignment to specific test sites predetermined on their anterior face of forearms) for 6 hours
Trial: NCT01946386
Drug: Daivobet® ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01946386
Drug: Dermovate® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01946386
Drug: Synalar® ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02398747
Drug: AZD2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
Trial: NCT01659307
Drug: Lactose powder
RxNorm normalized name: Lactose Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomised to placebo will receive 4 containers of placebo, 2 containers containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
Trial: NCT02567838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Aquagel) was administered rectally prior to probe insertion.
Trial: NCT01856309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.
Trial: NCT00944697
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oxycodone Naloxone tablets
Trial: NCT01022047
Drug: Budecort Aqua
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
Trial: NCT00005641
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005641
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005641
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00242866
Drug: GW274150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The tablets used in this study will contain either 5mg or 30mg of GW274150
Trial: NCT01433666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute intervention: single administration, capsulated form.
Trial: NCT06059326
Drug: HSK7653 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, HSK7653 50 mg Q2W, 12 weeks
Trial: NCT06059326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 0 mg Q2W, 12 weeks
Trial: NCT02462330
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injections of human albumin
Trial: NCT04497831
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation use
Trial: NCT03937154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT01878422
Drug: Arm B: FOLFIRI or FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: FOLFIRI or FOLFOX or Arm C: FOLFIRI or FOLFOX
Trial: NCT01598701
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.
Trial: NCT01598701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL 0.9% Sodium Chloride
Trial: NCT04512443
Drug: Daflon
RxNorm normalized name: Daflonex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).
Trial: NCT02017964
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02017964
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00925769
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of 500/650/750/900mg/m2 bid
Trial: NCT00074906
Drug: Venticute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment
Trial: NCT00604500
Drug: SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MF/F MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
Trial: NCT02223000
Drug: BIBV 308 SE solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04243850
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02223000
Drug: BIBV 308 SE capsule 1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02223000
Drug: BIBV 308 SE capsule 2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03263637
Drug: AZD4573
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4573 will be administered as a intravenous (IV) infusion.
Trial: NCT00858156
Drug: BG9928
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 75 mg single dose
Trial: NCT02512978
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
Trial: NCT02183571
Drug: Merck Glucophage® high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part I: Treatment A
Trial: NCT00484432
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin: 60mg/m² every 3 weeks, until cumulative dose of 550 mg/m²
Trial: NCT02022852
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy. Rest for 8 weeks and surgery followed.
Trial: NCT02022852
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XELOX 2 cycles (oxaliplatin 130mg/m2 ivgtt 2-6h day 1,capecitabine 1000 mg/m2 bid day 1-14 repeat every 3 weeks) → 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy → XELOX 1 cycle. Rest for 2 weeks and surgery followed.
Trial: NCT01205711
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01205711
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01205711
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03596385
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: long-term maintenance beta-blocker therapy
Trial: NCT00368550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 14-week treatment period
Trial: NCT01509300
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg IV on day-3 and -2
Trial: NCT04335578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo (PBO) at pre-specified time-points.
Trial: NCT00354536
Drug: GSK716155 subcutaneous injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albiglutide subcutaneous injection
Trial: NCT03613844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for DHA
Trial: NCT00670241
Drug: LEO 80185 vehicle
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily application
Trial: NCT03281577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-954 placebo-matching IV infusion.
Trial: NCT04056611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered orally.
Trial: NCT02972840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT04092582
Drug: MTPS9579A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTPS9579A IV infusion will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks through Week 46.
Trial: NCT04092582
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching MTPS9579A will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks thereafter through Week 46.
Trial: NCT03210246
Drug: Microgynon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of Microgynon for 3 cycles of 21 days each (day 1-21)
Trial: NCT03044171
Drug: In-office dental bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received the in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.
Trial: NCT03210246
Drug: Microgynon Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the treatment cycle 1-3, 7 doses of Microgynon placebo on Day 22-28 per cycle and after 3 treatment cycles 7 additional doses of Microgynon placebo on the 7 days after cycle 3 (day 84 - 91).
Trial: NCT04596631
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 52 weeks.
Trial: NCT04062890
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo Pill
Trial: NCT00193609
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 by mouth twice daily on days 1-14 of each 21 day cycle
Trial: NCT03956264
Drug: Kalinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gas mixture composed of 50% Nitrous Oxide and 50% Oxygen
Trial: NCT00003172
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00690274
Drug: BF2.649
FDA approved: no
EMA approved: no
PMDA approved: no
Description: up to 20mg per day
Trial: NCT00690274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: up to 20mg per day
Trial: NCT00003172
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01748084
Drug: Placebo (NaCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone
Trial: NCT03982407
Drug: 68Ga-PSMA-11 PET/MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PET/MRI exam-related patient visit will last approximately 2 to 2.5 hours, including 30-minute nursing assessment, 45-60 minutes for PSMA uptake and 60 minutes for PET/MRI scan. They will be contacted within the next 72 hours to complete a brief phone survey.
Trial: NCT03205553
Drug: Peritoneal Dialysis Solution/Dextrose 1.5%
RxNorm normalized name: PERITONEAL DIALYSIS SOLUTION/DEXTROSE 1.5% SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial reductions will be performed with silastic silo placement for staged reduction with adjuvant direct peritoneal resuscitation (DPR). A JP drain will be securely placed through the top of the silo beneath the fascia at the base of the small bowel mesentery for instillation of dialysate fluid and aspiration of peritoneal fluid. The sterile syringe will then be connected to the JP drain. The dialysate fluid administered via JP drain as a bolus infusion every 6 hours until the abdominal wall is closed (generally 3-5 days), but not to exceed 7 days maximum. Fluid will be warmed at bedside using dry heat not to exceed 37°C/98°F. The initial bolus infusion will be 10 mL/kg of dialysate. If tolerated, each subsequent infusion will be increased by 10 mL/kg up to a goal infusion of 40 mL/kg (to a maximum volume of 100 mL) as tolerated. Dialysate will dwell for 1 hour after instillation of fluid. Any excess fluid will then be removed via JP drain.
Trial: NCT01820026
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Second line therapy
Trial: NCT01332500
Drug: Sumatriptan/Naproxen combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan and Naproxen Sodium
Trial: NCT01332500
Drug: other oral triptans
RxNorm normalized name: TripTone Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
Trial: NCT03478332
Drug: Yangxinshi pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6g/tablet
Trial: NCT03478332
Drug: conventional coronary heart disease medicine
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the conventional treatment includes medicines treating coronary heart disease
Trial: NCT03478332
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangxinshi simulant
Trial: NCT00042289
Drug: kanamycin
RxNorm normalized name: Kanamycin
DrugBank: Kanamycin (DB01172)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: kanamycin (2nd line TB drug)
Trial: NCT00042289
Drug: amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: amikacin (2nd line TB drug)
Trial: NCT00042289
Drug: terizidone/cycloserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terizidone/cycloserine (2nd line TB drug)
Trial: NCT01567124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group.
Trial: NCT04779060
Drug: intrathecal fentanyle
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mic fentanyle added to heavy bupivacaine for spinal anesthesia
Trial: NCT02619552
Drug: Anti-TNF
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants in this arm receive an anti-TNF for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
Trial: NCT02619552
Drug: Anti-TNF
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants in this arm receive an anti-TNF for the treatment of perianal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
Trial: NCT02619552
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants in this arm receive steroids for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
Trial: NCT02165215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo (matched to etrolizumab) SC injection Q4W.
Trial: NCT03636984
Drug: recombinant TNF-α receptor: IgG Fc fusion protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg weekly
Trial: NCT04480879
Drug: AZD8154 nebuliser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebuliser suspension
Trial: NCT04480879
Drug: AZD8154 Placebo Monodose DPI presented in capsules
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose correspond to AZD8154 Monodose DPI formulation
Trial: NCT01706146
Drug: Non-coumadin Oral Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
Trial: NCT01823900
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of a combination tablet of Rosuvastatin 20mg and Olmesartan 40mg
Trial: NCT01823900
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of Rosuvastatin 20mg tablet and Olmesartan 40mg tablet
Trial: NCT00932100
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV dose per standard of care at the local institution
Trial: NCT01059591
Drug: GSK424887
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK424887 2mg, 10mg, 50mg, 100mg capsule
Trial: NCT01059591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GSK424887 2mg, 10mg,50mg, 100mg capsule
Trial: NCT03995550
Drug: LEO 142397
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A compound in development by LEO Pharma A/S
Trial: NCT03995550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo